全球结核病控制:过去、现在和未来

doi:10.3969/j.issn.2095-3755.2013.03.002

结核病与肺部健康杂志 ›› 2013, Vol. 2 ›› Issue (3): 143-149.doi: 10.3969/j.issn.2095-3755.2013.03.002

全球结核病控制:过去、现在和未来

Emilio，Dirlikov，刘宇红，Catharina，Van，Weezenbeek，Mario，Raviglione，Fabio，Scano

加拿大蒙特利尔,McGill大学人类学系(Emilio Dirlikov)；北京,中国疾病预防控制中心结核病防治临床中心(刘宇红)；马尼拉,世界卫生组织西太平洋地区办公室遏制结核病和消除麻风部(Catharina Van Weezenbeek)；日内瓦,世界卫生组织总部全球结核病规划司(Mario Raviglione)；北京,世界卫生组织驻华代表处遏制结核病组(Fabio Scano)

收稿日期:2013-08-09 出版日期:2013-09-30 发布日期:2013-09-30

Global tuberculosis control: then and now

Emilio Dirlikov, LIU Yu-hong, Catharina Van Weezenbeek, Mario Ra-viglione, Fabio Scano

Affiliation of authors: McGill University, Department of Anthropology, Montreal, Canada (Emilio Dirlikov); Clinical Centre on Tuberculosis, China CDC, China (LIU Yu-hong); Stop TB and Leprosy, World Health Organization, Manila, Philippines (Catharina Van Weezenbeek); Global TB Programme, World Health Organization, Geneva, Switzerland (Mario Raviglione); Stop TB Unit, World Health Organization, Beijing, China (Fabio Scano)

Received:2013-08-09 Online:2013-09-30 Published:2013-09-30

摘要/Abstract

摘要： 回顾全球抗击结核病的进展,阐述当前结核病控制工作中的主要挑战,包括耐多药结核病,以及HIV与Mtb双重感染等。最后以WHO制定的《消除结核病策略2016—2035年》作为结束。为此,检索了2007年至2013年5月23日在PubMed和Science Direct两个数据库的英文文献,搜索关键词为“肺结核”、“全球”、“控制”和“政策”。分别在PubMed和Science Direct搜索到145篇和68篇论文。排除了仅阐述某个国家或地区的文章及关于临床研究的文章后,对70篇文献进行了综述。此外,文章内容还包括WHO总部提供的背景资料,以及与有关的结核病专家进行的讨论。

Abstract: In this article, we review the progress made in the global fight against tuberculosis. We detail current challenges to control efforts, including MDR-tuberculosis and HIV/tuberculosis co-infection. We finish by highlighting developments in the WHO End TB strategy 2016—2035. A search for English articles was conducted on two electronic databases: PubMed and Science Direct. Articles were searched under the keywords “tuberculosis,” “global,” “control,” and “policy,” for 2007 to May 23, 2013. PubMed returned 145 articles, and Science Direct returned 68. Articles were further excluded if they focused on an individual country or region, or exclusively on clinical research. A final 70 articles were reviewed. Additional background information was assembled from information provided by WHO headquarters, and through discussions with relevant tuberculosis experts.

Emilio，Dirlikov，刘宇红，Catharina，Van，Weezenbeek，Mario，Raviglione，Fabio，Scano. 全球结核病控制:过去、现在和未来[J]. 结核病与肺部健康杂志, 2013, 2(3): 143-149. doi: 10.3969/j.issn.2095-3755.2013.03.002

Emilio Dirlikov, LIU Yu-hong, Catharina Van Weezenbeek, Mario Ra-viglione, Fabio Scano. Global tuberculosis control: then and now[J]. Journal of Tuberculosis and Lung Health, 2013, 2(3): 143-149. doi: 10.3969/j.issn.2095-3755.2013.03.002

参考文献

[1]World Health Organization. Global tuberculosis report 2012. Geneva: World Health Organization, 2012.
[2]Glaziou P, Falzon D, Floyd K, et al. Global epidemiology of tuberculosis. Semin Respir Crit Care Med, 2013, 34(1): 3-16.
[3]World Health Organization. Global tuberculosis report 2011. Geneva: World Health Organization, 2011.
[4]Brown TM, Cueto M,Fee E. The World Health Organization and the transition from “international” to “global” public health. Am J Public Health, 2006, 96(1): 62-72.
[5]McDougall JB. Tuberculosis and the World Health Organization. Tubercle, 1948, 29(9): 208-214.
[6]World Health Organization tuberculosis program for 1950. Public Health Rep, 1949, 64(35): 1117-1123.
[7]Long ER. The decline of tuberculosis as the chief cause of death. Proc Am Philos Soc, 1948, 92(3): 139-143.
[8]Bonah C. The ‘experimental stable’ of the BCG vaccine: safety, efficacy, proof, and standards, 1921—1933. Stud Hist Philos Biol Biomed Sci, 2005, 36(4): 696-721.
[9]Hart PD. Chemotherapy of tuberculosis; research during the past 100 years. Br Med J, 1946, 2(4482): 805-810.
[10]Keshavjee S,Farmer PE. History of tuberculosis and drug resistance. N Engl J Med, 2013, 368(1): 89-90.
[11]Maggi N, Pasqualucci CR, Ballotta R, et al. Rifampicin: a new orally active rifamycin. Chemotherapy, 1966, 11(5): 285-292.
[12]Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle, 1958, 39(5): 269-274.
[13]Valier H. At home in the colonies: the WHO-MRC trials at the Madras Chemotherapy Centre in the 1950s and 1960s//Condrau F,Worboys M. Tuberculosis then and now: perspectives on the history of an infectious disease. Montreal: McGill-Queen’s University Press,2010:213.
[14]Fox W. Problems of treatment of drug resistance in the developing countries. Tubercle, 1969, 50 Suppl: S55-65.
[15]World Health Organization Expert Committee on Tuberculosis. Eighth report. WHO technical report series No 290. Geneva: World Health Organization, 1964.
[16]Cueto M. The origins of primary health care and selective primary health care. Am J Public Health, 2004, 94(11): 1864-1874.
[17]World Health Organization. Declaration of Alma-Ata. International conference on primary health care, Alma-Ata, USSR, 6-12 September 1978. Geneva: WHO, 1978.
[18]United Nations. Sixty-fourth general assembly. Global strategy for health for all by the Year 2000. Resoultion 36/43. Geneva: United Nations, 1981.
[19]Raviglione MC,Pio A. Evolution of WHO policies for tuberculosis control, 1948—2001. Lancet, 2002, 359(9308): 775-780.
[20]BCG: bad news from India. Lancet, 1980, 1(8159): 73-74.
[21]Brimnes N. BCG vaccination and WHO’s global strategy for tuberculosis control 1948—1983. Soc Sci Med, 2008, 67(5): 863-873.
[22]World Health Organization. Tuberculosis control: Report of a joint IUAT/WHO Study Group. WHO technical report series No 671. Geneva: World Health Organization, 1982.
[23]Styblo K,Rouillon A. Tuberculosis. Health Policy Plann, 1991, 6(4): 391-397.
[24]Lienhardt C, Glaziou P, Uplekar M, et al. Global tuberculosis control: lessons learnt and future prospects. Nat Rev Micro-biol, 2012, 10(6): 407-416.
[25]World Health Organization. Forty-fourth world health assembly. Tuberculosis control programme. Resolutions and decisions resolution WHA 44.8. Geneva: World Health Organization, 1991.
[26]Chang KC, Sterling TR,Yew WW. Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Int J Tuberc Lung Dis, 2013, 17(6): 712.
[27]Marais BJ, Raviglione MC, Donald PR, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet, 2010, 375(9732): 2179-2191.
[28]Tuberculosis: a global emergency. World Health Forum, 1993, 14(4): 438.
[29]Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. China Tuberculosis Control Collaboration. Lancet, 1996, 347(8998): 358-362.
[30]Ogden J, Walt G,Lush L. The politics of ‘branding’ in policy transfer: the case of DOTS for tuberculosis control. Soc Sci Med, 2003, 57(1): 179-188.
[31]World Health Organization. Fifty-third world health assembly. Stop tuberculosis initiative. Resolutions and decisions re-solution WHA 53.1. Geneva: World Health Organization, 2000.
[32]Raviglione MC,Uplekar MW. WHO’s new Stop TB Strategy. Lancet, 2006, 367(9514): 952-955.
[33]World Health Organization. Sixty-second world health assembly. Prevention and Control of multidrug-resistant tuberulosis and extensively drug-resistant tuberculosis. Resolutions and decisions resolution WHA 62.15. Geneva: World Health Organization, 2009.
[34]Glaziou P, Floyd K, Korenromp EL, et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ, 2011, 89(8): 573-582.
[35]Dye C, Glaziou P, Floyd K, et al. Prospects for tuberculosis elimination. Annu Rev Public Health, 2013, 34: 271-286.
[36]Streptomycin treatment of pulmonary tuberculosis. Br Med J, 1948, 2(4582): 769-782.
[37]Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis, 2013, 13(6): 529-539.
[38]Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis, 2012, 54(4): 579-581.
[39]Zhao Y, Xu S, Wang L, et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012, 366(23): 2161-2170.
[40]Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J, 2012,[Epub ahead of print].
[41]Daley CL,Caminero JA. Management of multidrug resistant tuberculosis. Semin Respir Crit Care Med, 2013, 34(1): 44-59.
[42]Falzon D, Weyer K,Raviglione M. Drug-resistant tuberculosis: latest advances. Lancet Respir Med, 2013, 1(1): e9-e10.
[43]Raviglione MC,Ditiu L. Setting new targets in the fight against tuberculosis. Nat Med, 2013, 19(3): 263.
[44]Reichman LB,Lardizabal A. Drug-resistant tuberculosis: how are we doing? Int J Tuberc Lung Dis, 2013, 17(6): 711.
[45]Chiang CY, Van Deun A,Enarson DA. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. Int J Tuberc Lung Dis, 2013, 17(6): 714-718.
[46]Dheda K,Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet, 2012, 379(9817): 773-775.
[47]Lnnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010-50: cure, care, and social deve-lopment. Lancet, 2010, 375(9728): 1814-1829.
[48]Jeon CY,Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med, 2008, 5(7): e152.
[49]Jeon CY, Murray MB,Baker MA. Managing tuberculosis in patients with diabetes mellitus: why we care and what we know. Expert Rev Anti Infect Ther, 2012, 10(8): 863-868.
[50]Raviglione M,Krech R. Tuberculosis: still a social disease. Int J Tuberc Lung Dis, 2011, 15: Suppl 2: S6-S8.
[51]Romano M,Huygen K. An update on vaccines for tuberculosis——there is more to it than just waning of BCG efficacy with time. Expert Opin Biol Ther, 2012, 12(12): 1601-1610.
[52]Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160.
[53]Phillips PP, Nunn AJ,Paton NI. Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months? Int J Tuberc Lung Dis, 2013, 17(6): 807-809.
[54]Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182(5): 684-692.
[55]Raviglione M, Zumla A, Marais B, et al. A sustainable agenda for tuberculosis control and research. Lancet, 2012, 379(9821): 1077-1078.

全球结核病控制:过去、现在和未来

Global tuberculosis control: then and now

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价

友情链接